|
Angosto-Bazarra D, Guijarro A, Pelegrin P. Evolution of the gasdermin family and pyroptosis. Dev Comp Immunol. 2023 Dec;149:105060. doi: 10.1016/j.dci.2023.105060. Epub 2023 Sep 19. PubMed PMID: 37734430.
AÑO: 2023; IF: 2.7
|
37734430
|
Lozano-Rodriguez R, Avendano-Ortiz J, Montalban-Hernandez K, Ruiz-Rodriguez JC, Ferrer R, Martin-Quiros A, Maroun-Eid C, Gonzalez-Lopez JJ, Fabrega A, Terron-Arcos V, Gutierrez-Fernandez M, Alonso-Lopez E, Cubillos-Zapata C, Fernandez-Velasco M, Perez de Diego R, Pelegrin P, Garcia-Palenciano C, Cueto FJ, Del Fresno C, Lopez-Collazo E. The prognostic impact of SIGLEC5-induced impairment of CD8+ T cell activation in sepsis. EBioMedicine. 2023 Nov;97:104841. doi: 10.1016/j.ebiom.2023.104841. Epub 2023 Oct 25. PubMed PMID: 37890368; PubMed Central PMCID: PMC10630607.
AÑO: 2023; IF: 9.7
|
|
Weber ANR, Tapia-Abellan A, Liu X, Arostegui JI, Pelegrin P, Welzel T, Kuemmerle-Deschner JB. Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply. Rheumatology (Oxford). 2023 May 2;62(5):e168-e169. doi: 10.1093/rheumatology/keac718. No abstract available. PubMed PMID: 36562561.
AÑO: 2023; IF: 4.7
|
|
Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L, Bellosillo B, Such E, Soler-Espejo E, Martinez-Banaclocha H, Hernandez-Rivas JM, Marco-Ayala J, Martinez-Alarcon L, Linares-Latorre L, Garcia-Avila S, Amat-Martinez P, Gonzalez T, Arnan M, Pomares-Marin H, Carreno-Tarragona G, Chen-Liang TH, Herranz MT, Garcia-Palenciano C, Morales ML, Jerez A, Lozano ML, Teruel-Montoya R, Pelegrin P, Ferrer-Marin F. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. PubMed PMID: 38118408; PubMed Central PMCID: PMC10772462.
AÑO: 2023; IF: 10.6
|
|
Malhotra S, Hurtado-Navarro L, Pappolla A, Villar LMM, Rio J, Montalban X, Pelegrin P, Comabella M. Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure. Neurol Neuroimmunol Neuroinflamm. 2023 Mar 27;10(3):e200100. doi: 10.1212/NXI.0000000000200100. Print 2023 May. PubMed PMID: 36973075; PubMed Central PMCID: PMC10042441.
AÑO: 2023; IF: 7.8
|